S J Cohen

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007
  2. ncbi Targeting signal transduction pathways in colorectal cancer--more than skin deep
    Steven J Cohen
    Division of Medical Science, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 23:5374-85. 2005
  3. ncbi Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 31:1-5. 2008
  4. ncbi Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3213-21. 2008
  5. ncbi Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 53:513-8. 2004
  6. ncbi A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C307, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 66:287-94. 2010
  7. ncbi Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Colorectal Cancer 6:125-32. 2006
  8. ncbi A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497
    Int J Radiat Oncol Biol Phys 62:1345-50. 2005
  9. ncbi Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
    S J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Ann Oncol 20:1223-9. 2009
  10. ncbi Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008

Collaborators

Detail Information

Publications29

  1. ncbi Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer
    Kalyani Narra
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1691-9. 2007
    ..The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer...
  2. ncbi Targeting signal transduction pathways in colorectal cancer--more than skin deep
    Steven J Cohen
    Division of Medical Science, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111 2497, USA
    J Clin Oncol 23:5374-85. 2005
    ....
  3. ncbi Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 31:1-5. 2008
    ..Thus, we performed this phase I study to document the safety and obtain preliminary efficacy data for the combination of capecitabine, oxaliplatin, and bortezomib...
  4. ncbi Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3213-21. 2008
    ..We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical outcome in patients with mCRC...
  5. ncbi Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 53:513-8. 2004
    ....
  6. ncbi A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C307, Philadelphia, PA 19111 2497, USA
    Cancer Chemother Pharmacol 66:287-94. 2010
    ..We performed a phase I trial of imexon and gemcitabine to evaluate safety, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) in patients with advanced pancreatic cancer...
  7. ncbi Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Clin Colorectal Cancer 6:125-32. 2006
    ....
  8. ncbi A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497
    Int J Radiat Oncol Biol Phys 62:1345-50. 2005
    ..This randomized study was undertaken to determine whether the addition of 5-fluorouracil (5-FU) and mitomycin-C (MMC) to radiation therapy improves outcome in this patient population. Patients and..
  9. ncbi Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
    S J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Ann Oncol 20:1223-9. 2009
    ..This analysis was undertaken to explore whether patient and treatment characteristics impact the prognostic value of CTCs...
  10. ncbi Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Jeanes Hospital, Philadelphia, PA 19111 2497, USA
    Pancreas 37:154-8. 2008
    ....
  11. ncbi Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 74:55-9. 2009
    ....
  12. ncbi Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
    C Aggarwal
    Department of Medicine, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 24:420-8. 2013
    ..This secondary analysis assessed the relationship of the CTC number with carcinoembryonic antigen (CEA) and overall survival...
  13. ncbi Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma
    Kimberly M Brown
    Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Ave Philadelphia, PA 19027, USA
    Am J Surg 195:318-21. 2008
    ..For patients with borderline resectable pancreatic cancer, preoperative chemoradiation and standalone chemotherapy may allow for R0 resection and improved survival...
  14. ncbi Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 21:1301-6. 2003
    ..CONCLUSION: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer...
  15. ncbi Defining venous involvement in borderline resectable pancreatic cancer
    Yun Shin Chun
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Ann Surg Oncol 17:2832-8. 2010
    ..There is no consensus about what degree of venous impingement constitutes borderline resectability...
  16. ncbi Tumors of the esophagus, gastroesophageal junction, and stomach
    Margot Roberts Sweed
    Department of Nursing, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Oncol Nurs 25:61-75. 2009
    ..To review the incidence, risk factors, staging, and diagnosis of esophageal, gastroesophageal junction, and stomach cancers, as well as nursing challenges associated with managing patients with these tumors...
  17. ncbi Survival after pancreatectomy with major arterial resection and reconstruction
    Karyn B Stitzenberg
    Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Ann Surg Oncol 15:1399-406. 2008
    ..We hypothesize that resection of a tumor-involved hepatic artery (HA) or celiac artery (CA) with reconstruction may offer a survival benefit to patients whose tumors were traditionally regarded as unresectable...
  18. ncbi Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 8:2116-22. 2002
    ..Evaluation of once-daily dosing of S-1 in malignancies for which fluoropyrimidines have known antitumor activity is warranted...
  19. ncbi Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative
    Margaret A O'Grady
    Fox Chase Cancer Center Partners, Division of Extramural Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19046, USA
    J Natl Compr Canc Netw 5:875-82. 2007
    ..Partnership between academic and community oncologists produces a quality review process that is broadly applicable and adaptable to changing medical knowledge...
  20. ncbi Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma
    Andre A Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 69:358-63. 2007
    ....
  21. ncbi Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Oncol 32:S63-7. 2005
    ..Because response to preoperative treatment predicts clinical outcome, the utility of midtreatment PET scans to guide treatment decisions should be further explored in larger clinical studies...
  22. ncbi Changing patterns of bone and brain metastases in patients with colorectal cancer
    Mark L Sundermeyer
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111-2497, USA
    Clin Colorectal Cancer 5:108-13. 2005
    ..As survival improves for this patient population, clinicians should be aware of the potential for metastases at previously uncommon sites...
  23. ncbi Circulating tumor cells in colorectal cancer: past, present, and future challenges
    Benjamin P Negin
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Curr Treat Options Oncol 11:1-13. 2010
    ..Improvements in detection and characterization of CTC will hopefully lead to refinement of the surgical and chemotherapeutic treatment of colorectal cancer...
  24. ncbi Progress in the development of prognostic and predictive markers for gastrointestinal malignancies
    Crystal S Denlinger
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Curr Treat Options Oncol 8:339-51. 2007
    ....
  25. ncbi Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
    ..Expression of AURKA protein was analysed by immunohistochemistry. Cox-proportional hazard method, Kaplan-Meier curves and log-rank statistics were used to estimate and compare the hazard ratios and median survival between the groups...
  26. ncbi Drug development in pancreatic cancer: finally, biology begets therapy
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Gastrointest Cancer 32:91-106. 2002
    ..Currently, there is a renewed optimism that the clinical application of biologic understanding will lead to an improved outcome for patients with pancreatic cancer...
  27. ncbi Circulating tumor cells: evolving evidence and future challenges
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncologist 14:1070-82. 2009
    ..This review covers the different techniques available for isolation of CTCs, the clinical utility of CTCs in breast, prostate, and colon cancer, and future directions in this field...
  28. ncbi Novel targets in pancreatic cancer: focus on future paths to therapy
    Steven J Cohen
    Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA
    Expert Opin Ther Targets 10:771-5. 2006
    ....
  29. ncbi Global gene expression profiling of circulating tumor cells
    Denis A Smirnov
    Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
    Cancer Res 65:4993-7. 2005
    ..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...